A
Anjali S. Advani
Researcher at Cleveland Clinic
Publications - 312
Citations - 7494
Anjali S. Advani is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Population & Leukemia. The author has an hindex of 36, co-authored 292 publications receiving 6025 citations. Previous affiliations of Anjali S. Advani include Cleveland Clinic Lerner College of Medicine & Harvard University.
Papers
More filters
Journal ArticleDOI
Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
Hagop M. Kantarjian,Deborah A. Thomas,Jeffrey L. Jorgensen,Elias J. Jabbour,Partow Kebriaei,Michael Rytting,Sergernne York,Farhad Ravandi,Monica Kwari,Stefan Faderl,Mary Beth Rios,Jorge E. Cortes,Luis Fayad,Robert Tarnai,Sa A. Wang,Richard E. Champlin,Anjali S. Advani,Susan O'Brien +17 more
TL;DR: Inotuzumab ozogamicin shows promise as a treatment for refractory and relapsed ALL and was expressed in more than 50% of blasts in all patients.
Journal ArticleDOI
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark J. Levis,Farhad Ravandi,Eunice S. Wang,Maria R. Baer,Alexander E. Perl,Steven Coutre,Harry P. Erba,Robert K. Stuart,Michele Baccarani,Larry D. Cripe,Martin S. Tallman,Giovanna Meloni,Lucy A. Godley,Amelia Langston,Sergio Amadori,Ian D. Lewis,Arnon Nagler,Richard Stone,Karen W.L. Yee,Anjali S. Advani,Dan Douer,Wieslaw Wiktor-Jedrzejczak,Gunnar Juliusson,Mark R. Litzow,Stephen H. Petersdorf,Miguel A. Sanz,Hagop M. Kantarjian,Takashi Sato,Lothar Tremmel,Debra M. Bensen-Kennedy,Donald Small,B. Douglas Smith +31 more
TL;DR: Overall, lestaurtinib treatment after chemotherapy did not increase response rates or prolong survival of patients withFLT3 mutant acute myeloid leukemia in first relapse, and any conclusions regarding the efficacy of combining FLT3 inhibition with chemotherapy are limited.
Journal ArticleDOI
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
Anjali S. Advani,Bertrand Coiffier,Myron S. Czuczman,Martin Dreyling,James M. Foran,Eva Giné,Christian Gisselbrecht,Nicolas Ketterer,Sunita D. Nasta,Ama Z. S. Rohatiner,Ingo G.H. Schmidt-Wolf,Martin Schuler,Jorge Sierra,Mitchell R. Smith,Gregor Verhoef,Jane N. Winter,Joseph Boni,Erik Vandendries,Mark Shapiro,Luis Fayad +19 more
TL;DR: Inotuzumab ozogamicin has demonstrated efficacy against CD22(+) B-cell NHL, with reversible thrombocytopenia as the main toxicity.
Journal ArticleDOI
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.
Fabiola Traina,Valeria Visconte,Paul Elson,Ali Tabarroki,Anna M. Jankowska,Edy Hasrouni,Yuka Sugimoto,Hadrian Szpurka,Hideki Makishima,Christine L. O'Keefe,Mikkael A. Sekeres,Anjali S. Advani,Matt Kalaycio,Edward A. Copelan,Yogen Saunthararajah,S. T. Olalla Saad,Jaroslaw P. Maciejewski,Ramon V. Tiu +17 more
TL;DR: The role of molecular mutations as predictive biomarkers for response and survival in MDS patients treated with DNMT inhibitors is supported.
Journal ArticleDOI
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.
Wendy Stock,Selina M. Luger,Anjali S. Advani,Jun Yin,Richard C. Harvey,Charles G. Mullighan,Cheryl L. Willman,Noreen Fulton,Kristina Laumann,Greg Malnassy,Elisabeth Paietta,Edy Parker,Susan Geyer,Krzysztof Mrózek,Clara D. Bloomfield,Ben L. Sanford,Guido Marcucci,Michaela Liedtke,David F. Claxton,Matthew C. Foster,Jeffrey A. Bogart,John C. Grecula,Frederick R. Appelbaum,Harry P. Erba,Mark R. Litzow,Martin S. Tallman,Richard Stone,Richard A. Larson +27 more
TL;DR: Use of a pediatric regimen for AYA patients with newly diagnosed ALL up to age 40 years was feasible and effective, resulting in improved survival rates compared with historical controls, and CALGB 10403 can be considered a new treatment standard upon which to build for improving survival for AYAs with ALL.